Myostatin: The Muscle “Brake” Every Veterinarian Should Know About

When we think about maintaining or building muscle, we often focus on the things that stimulate muscle growth: exercise, adequate nutrition, protein, and rehabilitation.

But muscle health is also influenced by the body’s natural mechanisms for limiting muscle growth.

One of the most important of these mechanisms is myostatin.

For veterinary professionals, understanding myostatin provides an important window into why muscle loss can occur during periods of inactivity, aging, disease, or recovery—and why targeting the biology of muscle may be an important component of a comprehensive muscle health strategy.

What Is Myostatin?

Myostatin, also known as growth differentiation factor-8 (GDF-8), is a protein produced primarily by skeletal muscle. It belongs to the transforming growth factor-beta (TGF-β) superfamily and functions as a negative regulator of skeletal muscle mass.

Put simply:

Myostatin acts as a natural brake on muscle growth.

This is an important physiological function. The body does not want muscle to grow indefinitely. Myostatin helps regulate muscle development and maintain muscle mass within an appropriate range.

The problem arises when the balance between muscle-building and muscle-breakdown processes shifts toward loss.

The Balance Between Muscle Growth and Muscle Loss

Skeletal muscle is constantly being remodeled.

Muscle proteins are continuously synthesized, broken down, and replaced. Maintaining muscle mass requires an appropriate balance between these anabolic and catabolic processes.

Think of it as a muscle thermostat:

Muscle building signals

Lower muscle building signals lead to reduced protein synthesis and less muscle maintenance, resulting in decreased muscle mass.

Muscle limiting or catabolic signals

Higher muscle limiting signals increase protein degradation and reduce muscle growth, contributing to muscle loss.

Myostatin is one of the body's important mechanisms on the muscle-limiting side of this equation.

Research has shown that myostatin signaling can promote pathways involved in muscle protein degradation, including the ubiquitin-proteasome system, while also inhibiting processes associated with muscle growth.

This becomes particularly relevant when a patient is already predisposed to losing muscle.

Why Myostatin Matters in Veterinary Patients

Veterinary patients encounter many situations in which muscle loss becomes a concern.

Consider a dog recovering from TPLO surgery.

The affected limb may experience weeks of restricted activity. Reduced mechanical loading can rapidly contribute to muscle atrophy. At the same time, the physiological environment surrounding muscle changes during periods of disuse.

The same general concern applies to:

• Senior dogs experiencing age-related muscle loss
• Patients with osteoarthritis and reduced mobility
• Dogs recovering from orthopedic injury
• Patients undergoing postoperative rehabilitation
• Animals experiencing prolonged periods of inactivity
• Patients with chronic disease and associated muscle wasting

In these situations, simply providing adequate dietary protein may not address every biological factor influencing muscle preservation.

The question becomes: Can we also influence the signals that tell the body to limit muscle?

That is where myostatin becomes particularly interesting.

Fortetropin® and the Myostatin Connection

Fortetropin®, the proprietary bioactive ingredient in MYOS products, has been investigated for its effects on muscle biology, including its relationship with myostatin.

One of the most relevant veterinary studies evaluated 100 client-owned dogs undergoing TPLO surgery in a prospective, randomized, double-blind, placebo-controlled trial.

The dogs received either Fortetropin or a placebo for 12 weeks following surgery.

During the first eight weeks—when exercise was restricted—the placebo group experienced a significant increase in serum myostatin of approximately 2,892 pg/mL.

In contrast, serum myostatin did not significantly increase in the Fortetropin group. At the same time, dogs receiving Fortetropin did not experience the significant reduction in thigh circumference observed in the placebo group.

These findings are important because they connect two observations:

Fortetropin supplementation
↓
No significant rise in circulating myostatin during the period of forced exercise restriction
↓
Less reduction in thigh circumference

The study authors concluded that these findings support the use of Fortetropin to help prevent disuse muscle atrophy in canine patients undergoing TPLO.

It's More Than Simply "Blocking Myostatin"

It is tempting to describe Fortetropin as a simple myostatin blocker. The science is more nuanced.

A separate randomized, placebo-controlled crossover study evaluated single 6-g and 12-g doses of Fortetropin in healthy adult dogs. That study did not find a significant reduction in serum myostatin over the subsequent 72 hours. The researchers noted that the bioavailability, pharmacokinetics, and precise mechanism of action of Fortetropin in dogs require additional investigation.

This distinction matters.

The available evidence does not support the idea that Fortetropin immediately lowers circulating myostatin after every dose. Instead, clinical research suggests that ongoing supplementation may help prevent the rise in myostatin that can occur during periods of disuse, at least in certain clinical settings.

That is a much more clinically relevant way to think about the relationship.

Why Preventing a Rise in Myostatin Could Matter

For a patient experiencing muscle loss, the goal isn't necessarily to eliminate myostatin.

Myostatin serves an important physiological purpose.

The goal is to help maintain a healthier balance between the signals that promote muscle maintenance and those that promote muscle loss.

When a patient is immobilized or significantly less active, the body has fewer of the mechanical and metabolic signals that normally support muscle maintenance.

At the same time, muscle-regulatory pathways can shift toward atrophy.

If myostatin levels rise during this period, it may further reinforce the biological environment favoring muscle loss.

The TPLO research suggests Fortetropin may help interrupt part of that process by preventing the rise in circulating myostatin observed in placebo-treated dogs.

The Bigger Picture: Muscle Health Is About More Than Exercise

Exercise remains one of the most powerful stimuli for maintaining skeletal muscle.

But veterinary patients don't always have that option.

A dog recovering from surgery cannot simply "exercise more." A geriatric dog with significant osteoarthritis may not tolerate enough activity to provide an adequate anabolic stimulus. A patient with chronic disease may experience muscle loss despite consuming an otherwise appropriate diet.

This is why understanding the biology of muscle matters.

Muscle health is influenced by both the signals that build muscle and the signals that limit it.

Myostatin represents one of the body's most important muscle-growth regulators—and research involving Fortetropin suggests that nutritional intervention may influence this pathway during periods when muscle preservation is particularly important.

What This Means for Veterinary Practice

For veterinarians, myostatin provides another way to think about muscle loss.

Instead of viewing muscle atrophy solely as a consequence of inactivity, aging, or disease, we can recognize it as a biological process involving multiple signaling pathways.

That opens the door to a more comprehensive approach to muscle health that can include:

Nutrition + Rehabilitation + Appropriate Activity + Disease Management + Muscle-Specific Support

Fortetropin represents one nutritional approach being investigated within this broader framework.

Its relationship with myostatin is particularly relevant in patients facing periods of reduced activity, including postoperative and rehabilitation patients. In the TPLO study, daily Fortetropin supplementation was associated with maintenance of thigh circumference and prevention of the rise in serum myostatin observed in placebo-treated dogs during forced exercise restriction.

The Takeaway

Myostatin is essentially one of the body's natural brakes on skeletal muscle growth.

When muscle preservation is important—whether because of surgery, injury, aging, chronic disease, or reduced mobility—understanding and addressing the biological mechanisms behind muscle loss may be just as important as addressing activity and nutrition alone.

Research on Fortetropin provides evidence that it may help support muscle health in part by modulating the myostatin response during periods of muscle disuse.

For veterinary professionals, that makes myostatin more than an interesting molecular pathway.

It is an important piece of the muscle health puzzle.

Because sometimes, supporting muscle isn't just about turning the accelerator up. It's also about understanding the brakes.

References

White DA, Harkin KR, Roush JK, Renberg WC, Biller D. Fortetropin inhibits disuse muscle atrophy in dogs after tibial plateau leveling osteotomy. PLOS ONE. 2020.

Nugent Britt C, et al. In a Randomized, Placebo-Controlled Cross-Over Study, Administration of 6 and 12 G Fortetropin® Does Not Reduce Serum Myostatin in Healthy Adult Dogs Over 72-Hours. Frontiers in Veterinary Science. 2021.

Lee SJ, et al. Myostatin: A Skeletal Muscle Chalone. Annual Review of Physiology. 2023.